TITLE

CEPHEID NAMES IZASA AS EUROPEAN DISTRIBUTOR OF SMART CYCLER

PUB. DATE
July 2002
SOURCE
Worldwide Biotech;Jul2002, Vol. 14 Issue 7, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on a distribution agreement signed by Cepheid with Izasa SA.
ACCESSION #
6939485

 

Related Articles

  • In Brief.  // Ophthalmology Times;1/15/2004, Vol. 29 Issue 2, p4 

    Reports on global developments involving companies in the pharmaceutical industry in the U.S. Inclusion of Alcon by "Fortune Magazine" as one of the best 100 companies to work for in the U.S; Agreement between Coronado Industries Inc. and Izasa SA; Amount of the financial aid from ASLAM...

  • Occlutech defeats injunction request in Spain.  // Medical Device Daily;9/22/2009, Vol. 13 Issue 182, p7 

    The article reveals that Occlutech, along with its partner Izasa, has defeated an injunction request against sales and marketing activities in Spain. U.S. competitor AGA Medical launched the injunction request at the Commercial Court I of Barcelona. There are patent infringement and unfair...

  • CEPHEID GETS PATENT COVERING I-CORE REACTION VESSEL.  // Biotech Equipment Update;Aug2002, p1 

    Reports on the announcement made by Cepheid Inc. regarding the issuance of patent that covers a novel reaction vessel for use in the company's I-CORE (R) DNA amplification and detection modules. Feature of I-CORE module; Applications for which the company is commercializing its technology;...

  • FDA CLEARS STREP TEST FOR CEPHEID SMART CYCLER.  // Biotech Equipment Update;Jan2003, p1 

    Reports that Infectio Diagnostic-Strep B test for genetic assessment designed and developed by genetic assessment systems manufacturer Cepheid Inc. has been approved by U.S. Food and Drug Administration (FDA) for commercialization in U.S. markets. Bacterium present in pregnant women which can be...

  • CEPHEID REPORTS $2.8 MILLION 3RD QTR. REVENUES.  // Biotech Financial Reports;Dec2001, p3 

    Details the 2001 third quarter revenue of Cepheid, a biotechnology firm in Sunnyvale, California. Impact of increased sales of the Smart Cycler systems; Issuance of Series C convertible preferred stock; Cost of company operations.

  • CEPHEID GETS ISO 9001 CERTIFICATION.  // Biotech Equipment Update;Aug2002, p2 

    Reports on the International Standard Organization 9001 certification received by Sunnyvale, California-based Cepheid Inc. through Underwriters Laboratories Inc. Scope of the certification on the design, manufacture and service of DNA detection system and tests; Comments of the president and...

  • CEPHEID REPORTS NET LOSS OF $4.1 MILLION FOR 2ND QTR.  // Biotech Financial Reports;Sep2001, p2 

    Focuses on financial performance of Sunnyvale, California-based DNA testing systems developer Cepheid for the quarter ended June 30, 2001. Comparison with 2000 figures; Reasons for the net loss; Product sales for the quarter.

  • Cepheid's Xpert FII/FV assay gets CE mark.  // Diagnostics & Imaging Week;2/28/2008, Vol. 11 Issue 9, p12 

    The article offers information on the Xpert Hemosil FII and FV assay released by Cepheid and Instrumentation Laboratory.

  • Test Results. Weir, Kirsten // Current Science;9/2/2011, Vol. 97 Issue 1, p8 

    The article reports on the move of Cepheid to create a machine called GeneXpert, which is said to diagnose tuberculosis (TB) quickly and easily.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics